CU24428B1 - Derivados de quinolizinona como inhibidores de pi3k - Google Patents

Derivados de quinolizinona como inhibidores de pi3k

Info

Publication number
CU24428B1
CU24428B1 CU2016000195A CU20160195A CU24428B1 CU 24428 B1 CU24428 B1 CU 24428B1 CU 2016000195 A CU2016000195 A CU 2016000195A CU 20160195 A CU20160195 A CU 20160195A CU 24428 B1 CU24428 B1 CU 24428B1
Authority
CU
Cuba
Prior art keywords
pi3k inhibitors
sup
quinolizinone derivatives
quinolizinone
derivatives
Prior art date
Application number
CU2016000195A
Other languages
English (en)
Other versions
CU20160195A7 (es
Inventor
Nirmal Kumar Jana
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Dipak Raychand Lagad
Sachin Jaysing Mahangare
Venkata P Palle
Manojkumar Ramprasad Shukla
Anand Jagannath Tarage
Prashant Popatrao Vidhate
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53716533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24428(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20160195A7 publication Critical patent/CU20160195A7/es
Publication of CU24428B1 publication Critical patent/CU24428B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>Se divulgan compuestos de la fórmula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>sus formas tautoméricas, estereoisómeros, en donde R<sup>1</sup> y R<sup>4</sup> y n son como se define en la descripción. Dichos compuestos son útiles como inhibidores de la enzima PI3K.</p>
CU2016000195A 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k CU24428B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2182MU2014 2014-07-04
PCT/IB2015/054958 WO2016001855A1 (en) 2014-07-04 2015-07-01 Quinolizinone derivatives as pi3k inhibitors

Publications (2)

Publication Number Publication Date
CU20160195A7 CU20160195A7 (es) 2017-05-10
CU24428B1 true CU24428B1 (es) 2019-06-04

Family

ID=53716533

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000195A CU24428B1 (es) 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k

Country Status (25)

Country Link
US (1) US9944639B2 (es)
EP (1) EP3164400A1 (es)
JP (1) JP6291601B2 (es)
KR (1) KR20170082490A (es)
CN (1) CN106470996B (es)
AP (1) AP2016009661A0 (es)
AU (1) AU2015283671B2 (es)
BR (1) BR112017000132A2 (es)
CA (1) CA2954231A1 (es)
CL (1) CL2017000006A1 (es)
CO (1) CO2017000011A2 (es)
CR (1) CR20160600A (es)
CU (1) CU24428B1 (es)
EA (1) EA201692557A1 (es)
GE (1) GEP20186934B (es)
HK (1) HK1232227A1 (es)
IL (1) IL249674B (es)
MA (1) MA40250A (es)
MX (1) MX2017000208A (es)
PE (1) PE20170640A1 (es)
PH (1) PH12017500007A1 (es)
SG (1) SG11201610770PA (es)
SV (1) SV2017005354A (es)
UA (1) UA115296C2 (es)
WO (1) WO2016001855A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2879809T3 (es) * 2014-11-01 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de proteínas quinasas
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
EP3828184A4 (en) * 2018-08-21 2022-05-04 Medshine Discovery Inc. PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR
EP3959198A1 (en) * 2019-04-23 2022-03-02 Evotec International GmbH Modulators of the integrated stress response pathway
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
WO2021233227A1 (en) * 2020-05-16 2021-11-25 Fochon Pharmaceuticals, Ltd. Compounds as protein kinase inhibitors
AU2022325819A1 (en) * 2021-08-09 2024-02-29 Scorpion Therapeutics, Inc. Compounds that inhibit pi3k isoform alpha and methods for treating cancer

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AU2007347115A1 (en) 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
PL2137186T3 (pl) 2007-03-23 2016-09-30 Związki heterocykliczne i ich zastosowania
HRP20140147T1 (hr) 2007-03-23 2014-03-28 Amgen Inc. 3-supstituirani derivati hinolina ili hinoksalina i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
GEP20125635B (en) 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
EA201270051A1 (ru) 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения
AU2010266064A1 (en) 2009-06-25 2012-01-19 Amgen Inc. 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AU2010330875B2 (en) 2009-12-18 2013-08-01 Amgen Inc. Heterocyclic compounds and their uses
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20110306622A1 (en) 2010-06-11 2011-12-15 Calitoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected subjects
AU2011271462A1 (en) 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors
CA2803619A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocycle compounds and their uses
EP2588468B1 (en) 2010-07-01 2014-03-26 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
EP2588467A1 (en) 2010-07-01 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012003271A1 (en) 2010-07-02 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
EP2619209A1 (en) 2010-09-24 2013-07-31 Gilead Calistoga LLC Atropisomers of pi3k-inhibiting compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
AU2011323243A1 (en) 2010-11-04 2013-05-23 Amgen Inc. Heterocyclic compounds and their uses
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2013005567A (es) 2010-11-17 2013-10-30 Amgen Inc Derivados de quinolina como inhibidores de pik3.
JP2014501261A (ja) 2010-12-23 2014-01-20 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
PE20180318A1 (es) 2011-01-10 2018-02-09 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
EP2683377A1 (en) 2011-03-11 2014-01-15 Gilead Calistoga LLC Combination therapies for hematologic malignancies
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
CN103635183A (zh) * 2011-04-29 2014-03-12 埃克塞利希斯股份有限公司 使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
US20130143902A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
ES2600705T3 (es) 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos
SI2834231T1 (sl) 2012-04-04 2016-09-30 AmgenInc. Heterociklične spojine in njihove uporabe
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX357043B (es) 2012-07-04 2018-06-25 Rhizen Pharmaceuticals Sa Inhibidores selectivos de pi3k delta.
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
CN104768952B (zh) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
JP2015529195A (ja) 2012-08-14 2015-10-05 ギリアード カリストガ エルエルシー 癌を処置するための組合せ治療
GEP201706623B (en) 2012-10-16 2017-02-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
JP6125663B2 (ja) 2012-12-21 2017-05-10 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
NZ714710A (en) 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
US11352359B2 (en) 2013-07-02 2022-06-07 Rhizen Pharmaceuticals Ag PI3K protein kinase inhibitors
CN104447727B (zh) 2013-09-02 2018-04-27 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
CA2920059A1 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
HK1231477A1 (zh) 2014-06-13 2017-12-22 吉利德科学公司 磷脂酰肌醇3-激酶抑制剂
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
ES2900812T3 (es) 2014-06-24 2022-03-18 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
ES2879809T3 (es) * 2014-11-01 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores de proteínas quinasas
CN105130984B (zh) 2015-09-23 2017-03-29 前湾医药科技（深圳）有限公司 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用

Also Published As

Publication number Publication date
US9944639B2 (en) 2018-04-17
CL2017000006A1 (es) 2017-06-02
AP2016009661A0 (en) 2016-12-31
WO2016001855A1 (en) 2016-01-07
MA40250A (fr) 2017-05-10
IL249674B (en) 2019-06-30
CA2954231A1 (en) 2016-01-07
KR20170082490A (ko) 2017-07-14
IL249674A0 (en) 2017-02-28
MX2017000208A (es) 2017-05-01
CU20160195A7 (es) 2017-05-10
SG11201610770PA (en) 2017-01-27
GEP20186934B (en) 2018-12-10
EP3164400A1 (en) 2017-05-10
CN106470996A (zh) 2017-03-01
CN106470996B (zh) 2019-02-22
AU2015283671A1 (en) 2017-02-02
UA115296C2 (uk) 2017-10-10
PH12017500007A1 (en) 2017-05-15
CO2017000011A2 (es) 2017-04-10
JP2017519786A (ja) 2017-07-20
CR20160600A (es) 2017-03-07
EA201692557A1 (ru) 2017-05-31
US20170137421A1 (en) 2017-05-18
JP6291601B2 (ja) 2018-03-14
BR112017000132A2 (pt) 2018-01-09
SV2017005354A (es) 2018-10-05
HK1232227A1 (zh) 2018-01-05
PE20170640A1 (es) 2017-05-26
AU2015283671B2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
CL2019002612A1 (es) Compuestos macrocíclicos como inhibidores de la quinasa ros1.
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CU24428B1 (es) Derivados de quinolizinona como inhibidores de pi3k
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
EA201891211A1 (ru) Ингибиторы cxcr2
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CR20150462A (es) Inhibidores de erk y sus usos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
CR20160503A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos, como fungicidas
MX378288B (es) Inhibidores de pirimidina del fgfr4.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX373866B (es) Amidas heterocíclicas como inhibidores de cinasas.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY36499A (es) Uso de picolinamidas como fungicidas
AR101905A1 (es) Compuestos bicíclicos
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.